Meta-Analysis
Copyright ©The Author(s) 2015.
World J Virology. May 12, 2015; 4(2): 147-155
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.147
Table 1 Characteristics of studies included in the outcome 1
Ref.CountrySample size(Control/HIV)StudydesignHcy (µmol/L)
HHcyFolate (ng/mL)/Vitamin B12 (pg/mL)
ControlHIVControlHIV
Castagna et al[29]Italy20/14CS and CC of some patients10.8 ± 3.86.0 ± 2.2---
Muller et al[30]Norway15/21CS9.2 ± 7.39.0 ± 5.0---
Naisbitt et al[31]England33/33CS11.9 ± 4.714.5 ± 5.6---
Bernasconi et al[32]Swaziland80/73COS7.6 ± 3.68.7 ± 4.15% control; 12.3% HIV--
Vilaseca et al[33]Spain170/69COS6.2 (4.0-10.4)29.9 (5.5-23.3)250.7% HIVFolate 19.1 ± 7.5/ B12 455 ± 1601Folate 12.6 ± 6.7/ B12 481 ± 1811
de Larrañaga et al[34]Argentina31/128CS9.0 (7.2-13.0)29.0 (6.5-12.7)212.9% control; 16.4% HIVFolate 2.5 (2.1-3.1)2/B12 309 (268-477)2Folate 3.6 (2.5-5.6)2/B12 337.4 (222-493)2
Remacha et al[23]Spain128/235CS7.5 ± 7.814.3 ± 12.96.2% control;-B12 368.6 ± 219
Raiszadeh et al[35]United States127/249COS7.2 ± 2.77.4 ± 2.713.4% control; 16.90%--
Vigano et al[36]Italy19/23CS9.0 ± 5.011.0 ± 8.0-Folate 6.9 ± 1.7Folate 4.7 ± 1.5
Abdollahi and Shoar[37]Iran58/58CC12.6 ± 1.127.1 ± 10.291.4% HIV--
Borges-Santos et al[38]Brazil20/12CC13.9 ± 5.59.8 ± 1.6-Folate 7.5 (6.3-9.0)2/B12 288 ± 130Folate 1.9 (1.4-6.6)2/B12 367 ± 139
Deminice et al[39]Brazil10/23CS6.6 ± 1.59.4 ± 2.70% controls; 30.4% HIVFolate 11.7 ± 3.4/ B12 713.1 ± 110.1Folate 7.0 ± 2/B12 514.6 ± 99.3